Developments in Understanding Diffuse Noxious Inhibitory Controls: Pharmacological Evidence from Pre-Clinical Research

Mateusz Wojciech Kucharczyk,* Diego Valiente,* Kirsty Bannister Central Modulation of Pain Group, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, SE1 1UL., UK*These authors contributed equally to this workCorrespondence: Kirsty BannisterWolfson Centre f...

Full description

Bibliographic Details
Main Authors: Kucharczyk MW, Valiente D, Bannister K
Format: Article
Language:English
Published: Dove Medical Press 2021-04-01
Series:Journal of Pain Research
Subjects:
Online Access:https://www.dovepress.com/developments-in-understanding-diffuse-noxious-inhibitory-controls-phar-peer-reviewed-fulltext-article-JPR
_version_ 1818658238954995712
author Kucharczyk MW
Valiente D
Bannister K
author_facet Kucharczyk MW
Valiente D
Bannister K
author_sort Kucharczyk MW
collection DOAJ
description Mateusz Wojciech Kucharczyk,* Diego Valiente,* Kirsty Bannister Central Modulation of Pain Group, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, SE1 1UL., UK*These authors contributed equally to this workCorrespondence: Kirsty BannisterWolfson Centre for Age-Related Diseases, Guy’s Campus, King’s College London, London, SE1 1UL, UKTel +44 2078484617Fax +44 2078486806Email kirsty.bannister@kcl.ac.ukAbstract: Bulbospinal pathways regulate nociceptive processing, and inhibitory modulation of nociception can be achieved via the activity of diffuse noxious inhibitory controls (DNIC), a unique descending pathway activated upon application of a conditioning stimulus (CS). Numerous studies have investigated the effects of varied pharmacological systems on the expression status of a) DNIC (as measured in anaesthetised animals) and b) the descending control of nociception (DCN), a surrogate measure of DNIC-like effects in conscious animals. However, the complexity of the underlying circuitry that governs initiation of a top-down inhibitory response in reaction to a CS, coupled with the methodological limitations associated with using pharmacological tools for its study, has often obscured the exact role(s) of a given drug. In this literature review, we discuss the pharmacological manipulation interrogation strategies that have hitherto been used to examine the functionality of DNIC and DCN. Discreet administration of a substance in the spinal cord or brain is considered in the context of action on one of four hypothetical systems that underlie the functionality of DNIC/DCN, where interpreting the outcome is often complicated by overlapping qualities. Systemic pharmacological modulation of DNIC/DCN is also discussed despite the fact that the precise location of drug action(s) cannot be pinpointed. Chiefly, modulation of the noradrenergic, serotonergic and opioidergic transmission systems impacts DNIC/DCN in a manner that relates to drug class, route of administration and health/disease state implicated. The advent of increasingly sophisticated interrogation tools will expedite our full understanding of the circuitries that modulate naturally occurring pain-inhibiting pathways.Keywords: endogenous pain modulation, descending pain control, diffuse noxious inhibitory controls, descending control of nociception, conditioned pain modulation, monoamines
first_indexed 2024-12-17T03:54:12Z
format Article
id doaj.art-6548f946761d44f4b1a1c88e3e636537
institution Directory Open Access Journal
issn 1178-7090
language English
last_indexed 2024-12-17T03:54:12Z
publishDate 2021-04-01
publisher Dove Medical Press
record_format Article
series Journal of Pain Research
spelling doaj.art-6548f946761d44f4b1a1c88e3e6365372022-12-21T22:04:40ZengDove Medical PressJournal of Pain Research1178-70902021-04-01Volume 141083109564099Developments in Understanding Diffuse Noxious Inhibitory Controls: Pharmacological Evidence from Pre-Clinical ResearchKucharczyk MWValiente DBannister KMateusz Wojciech Kucharczyk,* Diego Valiente,* Kirsty Bannister Central Modulation of Pain Group, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, SE1 1UL., UK*These authors contributed equally to this workCorrespondence: Kirsty BannisterWolfson Centre for Age-Related Diseases, Guy’s Campus, King’s College London, London, SE1 1UL, UKTel +44 2078484617Fax +44 2078486806Email kirsty.bannister@kcl.ac.ukAbstract: Bulbospinal pathways regulate nociceptive processing, and inhibitory modulation of nociception can be achieved via the activity of diffuse noxious inhibitory controls (DNIC), a unique descending pathway activated upon application of a conditioning stimulus (CS). Numerous studies have investigated the effects of varied pharmacological systems on the expression status of a) DNIC (as measured in anaesthetised animals) and b) the descending control of nociception (DCN), a surrogate measure of DNIC-like effects in conscious animals. However, the complexity of the underlying circuitry that governs initiation of a top-down inhibitory response in reaction to a CS, coupled with the methodological limitations associated with using pharmacological tools for its study, has often obscured the exact role(s) of a given drug. In this literature review, we discuss the pharmacological manipulation interrogation strategies that have hitherto been used to examine the functionality of DNIC and DCN. Discreet administration of a substance in the spinal cord or brain is considered in the context of action on one of four hypothetical systems that underlie the functionality of DNIC/DCN, where interpreting the outcome is often complicated by overlapping qualities. Systemic pharmacological modulation of DNIC/DCN is also discussed despite the fact that the precise location of drug action(s) cannot be pinpointed. Chiefly, modulation of the noradrenergic, serotonergic and opioidergic transmission systems impacts DNIC/DCN in a manner that relates to drug class, route of administration and health/disease state implicated. The advent of increasingly sophisticated interrogation tools will expedite our full understanding of the circuitries that modulate naturally occurring pain-inhibiting pathways.Keywords: endogenous pain modulation, descending pain control, diffuse noxious inhibitory controls, descending control of nociception, conditioned pain modulation, monoamineshttps://www.dovepress.com/developments-in-understanding-diffuse-noxious-inhibitory-controls-phar-peer-reviewed-fulltext-article-JPRendogenous pain modulationdescending pain controldiffuse noxious inhibitory controlsdescending control of nociceptionconditioned pain modulationmonoamines
spellingShingle Kucharczyk MW
Valiente D
Bannister K
Developments in Understanding Diffuse Noxious Inhibitory Controls: Pharmacological Evidence from Pre-Clinical Research
Journal of Pain Research
endogenous pain modulation
descending pain control
diffuse noxious inhibitory controls
descending control of nociception
conditioned pain modulation
monoamines
title Developments in Understanding Diffuse Noxious Inhibitory Controls: Pharmacological Evidence from Pre-Clinical Research
title_full Developments in Understanding Diffuse Noxious Inhibitory Controls: Pharmacological Evidence from Pre-Clinical Research
title_fullStr Developments in Understanding Diffuse Noxious Inhibitory Controls: Pharmacological Evidence from Pre-Clinical Research
title_full_unstemmed Developments in Understanding Diffuse Noxious Inhibitory Controls: Pharmacological Evidence from Pre-Clinical Research
title_short Developments in Understanding Diffuse Noxious Inhibitory Controls: Pharmacological Evidence from Pre-Clinical Research
title_sort developments in understanding diffuse noxious inhibitory controls pharmacological evidence from pre clinical research
topic endogenous pain modulation
descending pain control
diffuse noxious inhibitory controls
descending control of nociception
conditioned pain modulation
monoamines
url https://www.dovepress.com/developments-in-understanding-diffuse-noxious-inhibitory-controls-phar-peer-reviewed-fulltext-article-JPR
work_keys_str_mv AT kucharczykmw developmentsinunderstandingdiffusenoxiousinhibitorycontrolspharmacologicalevidencefrompreclinicalresearch
AT valiented developmentsinunderstandingdiffusenoxiousinhibitorycontrolspharmacologicalevidencefrompreclinicalresearch
AT bannisterk developmentsinunderstandingdiffusenoxiousinhibitorycontrolspharmacologicalevidencefrompreclinicalresearch